Beam Therapeutics
20.48
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Beam Therapeutics
BEAM治疗公司开发用于治疗人类疾病的DNA碱基编辑技术并将其商业化。其许可的技术平台，其中包括使用基本编辑技术和相关技术，以扩大基本编辑的范围。该公司由David R.Liu、冯章、Alexis Komor、Nicole Gaudelli和J.Keith Joung于2017年1月25日创立，总部位于马萨诸塞州剑桥市。
Trade GPT
Similar Stocks
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.